
This Dinosaur Probably Chirped Like a Bird
In a paper published last week in the journal PeerJ, an international team of researchers describes a 163-million-year-old fossil found in northeastern China's Hebei Province. The fossil dinosaur, which they've dubbed Pulaosaurus qinglong, measures just 28 inches (72 centimeters) and is largely complete, giving researchers an unusually detailed look at its anatomy, including its surprisingly birdlike throat.
'Even when you have a dinosaur skeleton preserved, you don't always have these isolated bones preserved with other skull elements,' Xing Xu, a paleontologist at the Chinese Academy of Sciences in Beijing and an author of the paper, told The New York Times. 'They're very thin bones, very delicate and hard to preserve.'
In vertebrates, the vocal organs protect the airway and can produce sounds, including basic noises like hisses, groans, and grunts. In most living reptiles, these structures are made of cartilage and are relatively simple. Birds, however, have delicate, bony, flexible vocal organs that can make more complicated and diverse sounds.
Pulaosuarus' throat seems somewhere between the two. Its vocal structures appear to be similar to that of another dinosaur, Pinacosaurus, a kind of ankylosaur with a large, bony larynx that may have been flexible enough to produce birdlike chirps and tweets, the researchers told the Times.
The researchers believe that Pulaosaurus lived during the late Jurassic period and belonged to the same group of creatures that would later give rise to 'duck-billed' dinosaurs like hadrosaurs. But Pulaosaurus and Pinacosaurus are separated by millions of years of evolution, and neither belong to the group of dinosaurs that eventually produced birds. While it's possible they developed their vocal features independently, the presence of similar structures in such distinct species indicates that dinosaurs' ancient ancestors may have been pretty chirpy.
That means the origins of birdsong could lie in creatures that lived more than 230 million years ago, but it remains a mystery as to how or when modern birds' voice box, called the syrinx, evolved—or if any dinosaur shared their incredible vocal prowess.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Associated Press
an hour ago
- Associated Press
Ex Vivo Drug Response Platform From KYAN Shows Clinical Utility in Non-Hodgkin Lymphoma Patients
accurately predicted response in prospective cohort; results published in JCO Precision Oncology, a journal of ASCO SINGAPORE, July 28, 2025 / / -- A prospective clinical study published in JCO Precision Oncology, a journal of the American Society of Clinical Oncology (ASCO), confirms that KYAN Technologies' platform (Quadratic Phenotypic Optimization Platform, or QPOP) accurately predicts clinical response in relapsed/refractory non-Hodgkin lymphoma (R/R-NHL), including hard-to-treat subtypes where genomic testing often offers limited guidance. This prospective clinical validation study, conducted in 117 patients across two tertiary cancer centers, represents the largest published cohort to date using an ex vivo functional precision medicine platform in lymphoma. The results demonstrated meaningful clinical utility, reporting both objective response rates (ORR) and Kaplan-Meier survival outcomes, with significantly longer progression-free survival (PFS) in patients treated with combinations prioritized by the platform. The study showed that functionally guided therapies delivered not just predictive concordance, but measurable clinical benefit in a real-world setting. Key study findings: • 74.5 percent test accuracy in predicting clinical response • 59 percent ORR in patients treated with platform-guided combinations • Three-fold improvement in PFS compared to prior treatment line • Two-year survival analysis showed a statistically significant benefit over salvage therapy (P = 0.0191) 'This study reinforces the scientific rigor behind the platform by showing we can deliver reproducible, clinically concordant results across a large cohort of real patient samples,' said Edward K. Chow, PhD, KYAN Technologies' Chief Scientific Officer. 'We're especially grateful to the essential contributions of our clinical collaborators at the National University of Singapore (NUS), National University Hospital (NUH), and Singapore General Hospital (SGH). Their guidance, insights and commitment helped shape a platform that delivers timely, reliable, and actionable guidance for both physicians and patients.' directly measures how live tumor cells respond to therapy. Using a proprietary experimental design, the platform tests hundreds of clinically relevant drug treatments at once, including standard-of-care regimens, off-label therapies with known safety profiles, and novel options, and ranks them based on predicted treatment response. This functional, patient-specific readout provides oncologists with real-time guidance tailored to the biology of each tumor. 'This study marks a defining milestone in journey toward clinical adoption. With our clinical and analytical validation now published in a peer-reviewed journal, we're positioned to scale the platform in the U.S., starting with CLIA deployment and expanding through partnerships with leading clinicians and institutions,' said Hugo Saavedra, Chief Executive Officer of KYAN Technologies. The results underscore the broader potential of functional precision medicine to inform treatment decisions and combination design across oncology. By capturing how each patient's tumor responds to a breadth of drug regimens, not only guides clinical care but also offers insights that can support off-label strategy, clinical trial selection, and future drug development. About KYAN Technologies KYAN Technologies is a functional precision oncology company accelerating the discovery and deployment of effective cancer treatments. Its proprietary platform, uses ex vivo testing and combinatorial analytics to generate phenotypic response data from patient-derived tumor samples. This approach provides a clinically actionable layer of insight that complements genomic and transcriptomic tools. supports both patient care and drug development, helping clinicians identify tailored treatment options and enabling biopharma partners to prioritize combination strategies, select indications, and design smarter trials. Headquartered in Singapore, KYAN is expanding its U.S. presence to advance clinical deployment and strategic collaborations across oncology research and care. For media inquiries contact: Sudha Sruthi, Corporate Development email us here Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Associated Press
an hour ago
- Associated Press
NMPA Accepts sNDA for Ivonescimab in Combination with Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer
HONG KONG, July 28, 2025 /PRNewswire/ -- Akeso, Inc. ( ('Akeso' or the 'Company') is pleased to announce that the National Medical Products Administration (NMPA) has accepted the supplementary New Drug Application (sNDA) for ivonescimab (PD-1/VEGF bispecific antibody) in combination with chemotherapy as a first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC). This submission represents the third accepted application for ivonescimab in China, following previous filings for its combination therapy in EGFR-TKI resistant locally advanced or metastatic non-squamous NSCLC (nsq-NSCLC), as well as its monotherapy for first-line treatment of PD-L1 positive advanced NSCLC. PD-1 combined with chemotherapy has become a cornerstone in cancer therapy. The sNDA for ivonescimab's new indication is based on the strong positive outcomes from its Phase III trial (AK112-306/HARMONi-6 study), which showed that ivonescimab combined with chemotherapy is superior to tislelizumab plus chemotherapy. Building on the success of its head-to-head comparison with pembrolizumab, ivonescimab's ability to outperform PD-1 combination therapy marks a significant step forward in the evolution of global cancer immunotherapy. Currently, ivonescimab is involved in over 12 registrational/Phase III clinical trials worldwide, including six head-to-head studies with PD-1/L1 inhibitors. These trials span a diverse range of malignancies, such as various subtypes of lung cancer, first-line colorectal cancer, first-line head and neck squamous cell carcinoma, first-line biliary tract cancer, first-line pancreatic cancer, and first-line triple-negative breast cancer, among others. Ivonescimab has established a broad and strategic footprint across key cancer immunotherapy indications. As part of the company's 'IO+ADC' 2.0 oncology strategy, ivonescimab is positioned as a cornerstone agent in immuno-oncology, being evaluated in combination with innovative therapies targeting novel mechanisms and pathways. Forward-Looking Statement of Akeso, Inc. This announcement by Akeso, Inc. ( 'Akeso') contains 'forward-looking statements'. These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law. About Akeso Akeso (HKEX: is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 24 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available, and 2 new drugs with 2 new indications are under regulatory review for approval. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise. For more information, please visit and follow us on Linkedin. View original content: SOURCE Akeso, Inc.
Yahoo
3 hours ago
- Yahoo
A New COVID Variant Is Here, And It's More Transmissible — Here Are The Signs And Symptoms
A new COVID variant known as NB.1.8.1 has made landfall in the United States. As of late May, the variant, which was first detected in China this past January, accounted for 10% of the SARS-CoV-2 sequences tested from around the world, recent surveillance data found. That's a significant jump from 2.5% four weeks prior. A Centers for Disease Control and Prevention (CDC) spokesperson told HuffPost that the agency is in regular contact with international partners about the activity of NB.1.8.1. Up until late May, only 20 NB.1.8.1 sequences had been identified in the U.S. — that's below the threshold needed for a variant to appear on the agency's COVID dashboard. (As soon as its prevalence increases, NB.1.8.1 will pop up on the tracker, the spokesperson added.) It's nerve-wracking to hear that a new variant is making the rounds, but infectious disease specialists say there are no glaring differences between the symptoms of NB.1.8.1 and those caused by other versions of SARS-CoV-2. 'Currently it appears that NB.1.8.1 would have similar symptoms to other COVID variants that have recently been circulating,' Dr. Zachary Hoy, a pediatric infectious disease specialist with Pediatrix Medical Group in Nashville, Tennessee, told HuffPost. Here's what to know about the newest COVID variant that's gaining traction around the world. NB.1.8.1's mutations likely make it more transmissible. Compared to the currently dominant variant in the U.S. (LP.8.1), NB.1.8.1 has a handful of new mutations on the spike protein that may enhance its ability to bind to our cells, according to the World Health Organization (WHO). The agency suspects these mutations will increase the virus's transmissibility and, potentially, diminish the effectiveness of neutralizing antibodies that prevent pathogens from latching to our cells. In other words, the variant may be skilled at dodging some of our immune defenses, research suggests. Here are the signs and symptoms doctors are seeing with NB.1.8.1. According to Dr. Amesh Adalja, an infectious diseases expert and senior scholar at the Johns Hopkins University Center for Health Security, NB.1.8.1's symptoms are pretty much the same as those seen with other SARS-CoV-2 variants. Two of COVID's hallmark symptoms are a mild but persistent dry cough and nasal congestion, Hoy said. Many people who come down with COVID are also hit with fatigue and tiredness. 'An infected person can still make it through the day, but they are resting more and feel more tired throughout the day,' Hoy said. Other common symptoms include a fever, chills, a sore throat and muscle aches. 'Some have described recent variants as less intense symptoms as compared to wintertime influenza viruses, but both can have severe symptoms,' Hoy said. There's no evidence suggesting the variant causes more severe disease or an uptick in hospitalizations or deaths, the WHO states. The only noticeable aspect, as of now, is that it's rising in prevalence, Adalja said. How effective are the vaccines against NB.1.8.1? It's too early to know exactly how effective the shots are — as the research on NB.1.8.1 is limited since it's so new — but scientists expect the shots to hold up well. NB.1.8.1 broke off from the Omicron JN.1 lineage, which the 2024-2025 vaccines target. 'The ability of the vaccines to prevent severe illness is intact though protection versus infection is limited and transient,' Adalja said. Anyone who is at risk of severe disease should stay up-to-date with the shots. 'Those in older populations or with underlying immune disorders or on immune-decreasing medications would benefit more from vaccination or those with increased exposure such as healthcare workers,' Hoy added. So if you have a condition that puts you at risk, it's worth getting vaccinated if it's been more than six months since your last vaccine or bout of COVID, Adalja advises. He also added that those who are low-risk likely do not need to go out and get another shot. Know when to treat NB.1.8.1 at home and when to go visit a doctor. Most people will be able to recover at home by resting and staying hydrated. While you're sick, acetaminophen and ibuprofen can help alleviate muscle aches and fevers, Hoy said. And, in most cases, symptoms should clear up within a week. For those who are at risk for severe disease, including older adults and people who are immune-compromised, it's worth contacting a physician as they can prescribe antivirals — Paxlovid and Molnupiravir — that can significantly lower the risk of severe complications and death. As was the case with previous variants, these antivirals work best when started within five days of symptom onset. As for when you should go to an urgent care or emergency room? When you have chest pain, have a hard time waking up or staying awake, or feel confused and disoriented, the CDC advises. Hoy says the most concerning symptom he warns patients about is difficulty breathing. 'If you have COVID or COVID-like illness and have worsening trouble breathing or chest pain, you should be evaluated at your doctor's office, urgent care or the ER,' he said. Related... RFK Jr. Says COVID Shot Will No Longer Be Advised For Healthy Kids, Pregnant Women COVID Cases Are Rising This Summer, But Not All The Data Shows It — Here's Why People Are Reporting A Frightening COVID Symptom Right Now — Here's What To Know